Navigation Links
Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
Date:9/12/2007

Impact of Human Serum

Albumin on Oritavancin In

vitro Activity against

Staphylococcus aureus

E-1627a Poster Baines Activity of

Metronidazole,

Vancomycin and

Oritavancin

against Epidemic

Clostridium difficile

spores

About Oritavancin

Oritavancin is a novel semi-synthetic lipoglycopeptide antibiotic candidate with potent bactericidal (killing) activity against a broad spectrum of gram-positive bacteria. The product candidate has been tested in over 1500 patients and has completed two Phase 3 studies for the treatment of complicated skin and skin structure infection (cSSSI) in which the primary endpoints were met. Targanta believes oritavancin's properties may give it distinct advantages over currently marketed therapies and expects to submit a New Drug Application to the U.S. Food and Drug Administration in the first quarter of 2008 seeking to commercialize oritavancin for the treatment of cSSSI.

About Targanta Therapeutics

Targanta Therapeutics Corporation is a privately held biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company's pipeline includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic, for which Targanta intends to seek U.S. regulatory approval in early 2008, as well as a number of antibacterial agents in pre-clinical development. The company has operations in Cambridge, MA, Indianap
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Emerging technology companies receive significant funding
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. BIO 2007: Wisconsin makes its presence felt
5. TDS trades markets to gain Duluth presence
6. West Coast VC Establishes Midwest Presence in Madison
7. Sony Bets Heavy on Wisconsin Digital Entertainment Presence
8. NameProtect releases annual list of top trademarkers
9. Doyle says new contracts saving state more than $16 million annually
10. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
11. Annual Bioethics Forum to explore genetic testing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...NG,Nov.25/PRNewswire-Asia/--SinovacBiotechLtd.(SVA...dtodaythatitexecuted,ajointventure(JV)agreementtoe...SinovacDalian).TheJVwillresearch,develop,produce,a...buteitsexpertise,andexperienceindevelopingandcomme...ingitslanduserights,manufacturingfacilitiesand,est...
(Date:11/24/2009)...se is available in German . , Whether it,s ...RFID tags (Radio Frequency Identification) are inc...ey make it possible to label objects or goods and ...e appropriate scanner can read and process the dat...xed to goods under production conditions of up to ...
(Date:11/24/2009)... The New York investment bank KTA Capi...has agreed an AU$6.7 mil convertible note private ...private placement was arranged by KTA Capital as N... New York (PRWEB) November ...nk KTA Capital, LLC ("KTA Capital") has ...
(Date:11/24/2009)...AVIK,Iceland,November24/PRNewswire-FirstCall/--deC...ithasreceivednoticefrom,theNasdaqStockMarketthattr...November30,2009andaForm25-NSEwillbefiledwiththe,Se...E,scommonstock,fromlistingonNasdaq,unlessthecompan...el.Thecompanyhasfiledsuchanappeal,which,willstayth...
Breaking Biology Technology:Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Intelligence inside metal components 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3
...VA, Calif., Sept. 4 Volcano,Corporation (Nasdaq: ...VUS),and functional measurement (FM) products desi...cular and structural heart diseases, said today th...07 Healthcare Conference on,Tuesday, September 11....and chief executive,officer, will begin at 4 p.m.,...
...ALE, Fla., Sept. 4 Imaging,Diagnostic Systems, In...optical breast cancer imaging systems, has shipped...iversiti Putra Malaysia (UPM) in Kuala Lumpur,Mala...o: http://www.newscom.com/cgi-bin/prnh/20040412/I...PM,s academic facility within the,jurisdiction of ...
...Roles as Vice Chairman of The Foundry and Advisor ... MENLO PARK, Calif., Sept. 4 Morgenthaler Ventur...ding venture capital firm focused on,life science ...unced the,addition of Hank Plain as partner in its...preneurial experience and deep knowledge of the me...
Other Biology Technology:Volcano Corporation Presentation at Bear Stearns Conference to be Webcast 2Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia 2Hank Plain Joins Morgenthaler Ventures as Partner 2Hank Plain Joins Morgenthaler Ventures as Partner 3
(Date:11/24/2009)... weakened and flabby arteries from collapsing have...e stents are no longer needed -- once the arteries...usly, doctors had no choice but to leave them in p...rsity,s Department of Biomedical Engineering has d...carries drugs where they,re needed, then dissolves...
(Date:11/24/2009)...ntarctica has long held secrets of the earth,s his... there has been very little information on the env...ce for millions of years. Now, a team of researche...n funded to the tune of $10 million dollars by the...e bottom of things literally. These scientists wi...
(Date:11/23/2009)...search presents strong evidence that the "synergis... traffic-related pollution and indoor endotoxin ca... other exposure alone. , Environmental health ...llege of Medicine have shown that children exposed...and indoor endotoxin during early life are six tim...
Breaking Biology News(10 mins):A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Organic Counts 3A Organic Valley Launches First Online Calculator to Measure Personal Impact of Food Choices 58299 1Organic Counts 3A Organic Valley Launches First Online Calculator to Measure Personal Impact of Food Choices 58299 2Organic Counts 3A Organic Valley Launches First Online Calculator to Measure Personal Impact of Food Choices 58299 3Organic Counts 3A Organic Valley Launches First Online Calculator to Measure Personal Impact of Food Choices 58299 4Corn Refiners Association Comments on Findings in Recent Report on Sugars and High Blood Pressure 58297 1Corn Refiners Association Comments on Findings in Recent Report on Sugars and High Blood Pressure 58297 2aTyr Pharma to Present at Japan Biopharma Partnering Conference 58295 1aTyr Pharma to Present at Japan Biopharma Partnering Conference 58295 2
...fically counteracts the mechanisms of human cells ...cial viral protein marks protective cellular prote...s the cell,s supply. A team of researchers in Heid...Keppler demonstrated this mechanism for the first ...or a novel treatment strategy. , Another importa...
... an international initiative to develop standards ...ensor networks over the Internet. , Dr Kerry Tay... co-chair the World Wide Web Consortium,s (W3C) Se...bator group is developing an ontology for differen...enable sensors to interact using the Web, in the W...
...one in 1,000 American babies are born deaf. The nu...0% of seniors in the United States experiencing so...aring aid, and shouting at aging in-laws, may soon...ed geneticist and hearing loss expert at Tel Aviv ... deafness. , Prof. Karen Avraham of the Departme...
Other Biology News:HIV dearms protective protein in cells 2HIV dearms protective protein in cells 3Scaling the wall of deafness 2Scaling the wall of deafness 3
Chicken Anti-Human Quinolinate phosphoribosyltransferase Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
Mouse Anti-Y14 Monoclonal Antibody, Unconjugated, Clone 4C4 from Abcam
ZOOM® IEF Fractionator from Invitrogen
Agarose from BioPioneer
Biology Products: